Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL(+) leukemic cells and induces apoptosis

被引:253
|
作者
GambacortiPasserini, C
leCoutre, P
Mologni, L
Fanelli, M
Bertazzoli, C
Marchesi, E
DiNicola, M
Biondi, A
Corneo, GM
Belotti, D
Pogliani, E
Lydon, NB
机构
[1] IST NAZL TUMORI,DIV EXPT ONCOL D & MED ONCOL C,I-20133 MILAN,ITALY
[2] UNIV MILAN,S GERARDO HOSP,SECT HEMATOL,MONZA,ITALY
[3] UNIV MILAN,S GERARDO HOSP,DIV PEDIAT HEMATOL,MONZA,ITALY
[4] IST EUROPEO ONCOL,DIV EXPT ONCOL,MILAN,ITALY
[5] NOVARTIS INT INC,ONCOL RES DEPT,BASEL,SWITZERLAND
关键词
BCR/ABL; CML; ALL; tyrosine kinase inhibitors; apoptosis;
D O I
10.1006/bcmd.1997.0155
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The BCR/ABL fusion protein transforms myeloid stem cells. Both chronic myelogenous leukemias (CML) and a subset of acute lymphoblastic leukemias (ALL) are associated with the expression of BCR/ABL proteins. This knowledge has nor yet been translated into any specific tool to control ABL driven neoplastic cells growth, CGP57148B is an ATP-competitive inhibitor of the ABL protein kinase; it has been shown to inhibit the kinase activity of ABL both in vitro and in vivo and to inhibit the growth of v-abl and bcr/abl transfectants, as well as the in vitro formation of bone marrow (BM)-derived colonies in the presence of growth factors in some CML patients. These studies were performed to investigate the activity of CGP57148B on the spontaneous proliferation of both fresh and cultured, leukemic and normal, BCR/ABL positive and negative cells, and to study its mechanism of action. Six cell lines derived from BCR/ABL+ leukemias (K562, BV173, KCL22, KU812, MC3, LAMA84), thirteen BCR/ABL negative lines, both neoplastic(KG1, SU-DHL-1, U937, Daudi, NB4, NB4.306) and derived from normal cells (PHA blasts, LAK, fibroblasts, LCL, renal epithelial cells, endothelial cells, CD34(+) cells), and 14 fresh leukemic samples were tested using a tritiated thymidine uptake assay. The in vivo phosphorylation of the BCR/ABL protein was evaluated by western blot, while apoptosis was detected by the annexin V/propidium binding test. The induction of differentiation was assayed by immunofluorescence using multiple antibodies. All six BCR/ABL(+) lines showed a dose dependent inhibition of their spontaneous proliferative rate, which was not accompanied by differentiation. The treatment caused, within minutes, dephosphorylation of the BCR/ABL protein, followed in 16-24 hours by a decrease in cycling cells and induction of apoptosis, No significant inhibition of DNA synthesis was observed in any BCR/ABL negative normal or neoplastic line at concentrations less than or equal to 3 mu M, with the exception of fibroblasts and CD34 cells, Proliferation inhibition was observed also when using fresh samples obtained from two Ph+ ALL and 12 consecutive CML patients. Induction of apoptosis was observed in these samples too. The activity of CGP57148B can be monitored in ex vivo isolated or cultured cells using a simple and reproducible assay, without the need for exogenously added growth factors. This molecule possibly exerts its effects through the inhibition of the kinase activity of BCR/ABL and the subsequent initiation of apoptosis, without inducing cell differentiation. Some normal cells are also affected.
引用
收藏
页码:380 / 394
页数:16
相关论文
共 50 条
  • [41] Downstream effectors of activated ABL kinase in hematopoietic cells mediated by p210BCR/ABL, p190BCR/ABL, and TEL/ABL.
    Okuda, K
    Golub, T
    Gilliland, DG
    Griffin, JD
    BLOOD, 1995, 86 (10) : 1735 - 1735
  • [42] Temperature shift downregulates BCR/abl: Tyrosine kinase activity and decreases resistance of hematopoietic cells to apoptosis.
    de Aos, IE
    Inai, Y
    Jain, SK
    Aish, L
    Varticovski, L
    BLOOD, 1998, 92 (10) : 243B - 243B
  • [43] INHIBITION OF APOPTOSIS BY bcr-abl FUSION GENE IN K562 CELLS
    王春红
    孙秉中
    袁跃传
    ChineseJournalofCancerResearch, 1999, (03) : 174 - 176
  • [44] The dual Src/Abl kinase inhibitor SKI-606 effectively inhibits Bcr-Abl kinase activity and reduces proliferation of CML primitive progenitor cells.
    Konig, Heiko
    Sindhu, Simran K.
    Boschelli, Frank
    Holyoake, Tessa L.
    Forman, Stephen J.
    Bhatia, Ravi
    BLOOD, 2006, 108 (11) : 400A - 400A
  • [45] Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts
    Nimmanapalli, R
    O'Bryan, E
    Bhalla, K
    CANCER RESEARCH, 2001, 61 (05) : 1799 - 1804
  • [46] EXPRESSION OF BCR AND BCR-ABL FUSION TRANSCRIPTS IN NORMAL AND LEUKEMIC-CELLS
    COLLINS, S
    COLEMAN, H
    GROUDINE, M
    MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (08) : 2870 - 2876
  • [47] Comparison of the intrinsic kinase activity and substrate specificity of c-Abl and Bcr-Abl
    Wu, JZJ
    Phan, W
    Lam, KS
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (17) : 2279 - 2284
  • [48] Down-modulation of p210(bcr/abl) induces apoptosis/differentiation in K562 leukemic blast cells
    Deora, AB
    Miranda, MB
    Rao, SGA
    TUMORI, 1997, 83 (04) : 756 - 761
  • [49] Brefeldin A Induces Apoptosis, Inhibits BCR-ABL Activation, and Triggers BCR-ABL Degradation in Chronic Myeloid Leukemia K562 Cells
    Zhang, Jin-Man
    Wang, Cui-Fang
    Wei, Mei-Yan
    Dong, Hui
    Gu, Yu-Cheng
    Mo, Xiao-Mei
    Shao, Chang-Lun
    Liu, Ming
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (06) : 1091 - 1101
  • [50] BCR-ABL-transformed GMP as myeloid leukemic stem cells
    Minami, Yosuke
    Stuart, Scott A.
    Ikawa, Tomokatsu
    Jiang, Yong
    Banno, Asoka
    Hunton, Irina C.
    Young, Dennis J.
    Naoe, Tomoki
    Murre, Cornelis
    Jamieson, Catriona H. M.
    Wang, Jean Y. J.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (46) : 17967 - 17972